Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer
Status:
Unknown status
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
Research Hypothesis: icotinib administered in combination with gemcitabine has an acceptable
safety profile in subjects with locally advanced, unresectable or metastatic pancreatic
adenocarcinoma.The primary objective is to determine the safety profile of icotinib in
combination with gemcitabine in subjects with locally advanced, unresectable or metastatic
pancreatic adenocarcinoma.